Study to Treat Major Depressive Disorder With a New Medication

Status Completed

Clinical Trial Summary

This project is designed to examine the neuronal KCNQ2/3 potassium (K+) channel subtype as a novel treatment target for mood disorders through the administration of the KCNQ-selective channel opener ezogabine (Potiga, GlaxoSmithKline; FDA-approved for the treatment of seizure disorders).

Clinical Trial Description

Depressive disorders are among the most disabling medical conditions worldwide and currently available treatments fall short of addressing this large public health burden. Dysfunction within the brain reward system is emerging as a core feature of depressive disorders, in particular related to deficits in motivation, interest, and response to pleasure (e.g., anhedonia: markedly diminished response to pleasure). Evidences from a series of preclinical studies from our group highlighted the KCNQ subtype of neuronal potassium (K+) channel as a novel target for the treatment of depressive disorders and our human pilot study showed a reduction in anhedonia and related symptoms, and an increased brain response to reward (as measured by functional magnetic resonance imaging [fMRI]) following treatment with ezogabine. Building on this data, the current project will assess reward circuit activity following treatment with ezogabine in depressed patients with a current depressive disorder (Major depressive disorder [MDD], persistent depressive disorder, other specified depressive disorder) and anhedonia (defined by a score ≥ 20 on the Snaith-Hamilton Pleasure Scale [SHAPS]), using fMRI to investigate the cortico-striatal circuit to reward. This study represents the first part of the R61/R33 National Institutes of Health (NIH) founded project. A clear increase in reward circuit activation in at least one ezogabine treatment group compared to placebo, given acceptable tolerability, will constitute a "go" and the project will move to the next phase (R33), where we aim to examine the relationship between treatment, reward circuit activity, and behavioral and clinical outcomes in a larger, confirmatory efficacy trial of ezogabine for depression with anhedonia. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03043560
Study type	Interventional
Source	Icahn School of Medicine at Mount Sinai
Contact
Status	Completed
Phase	Phase 2
Start date	September 25, 2017
Completion date	August 30, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01316926` - Paxil CR Bioequivalence Study Brazil	Phase 1
Recruiting	`NCT06187454` - Transcranial Direct Current Stimulation for Depression	N/A
Completed	`NCT04469322` - Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression	N/A
Recruiting	`NCT05768126` - Prediction of ECT Treatment Response and Reduction of Cognitive Side-effects Using EEG and Rivastigmine	Phase 4
Completed	`NCT03219879` - Telephone-administered Relapse Prevention for Depression	N/A
Recruiting	`NCT06038721` - Unified Protocol: Community Connections	N/A
Completed	`NCT04091139` - Research of Unified Protocol for the Treatment of Common Mental Disorders in Adolescents in Hong Kong	Phase 2/Phase 3
Completed	`NCT00069459` - Seasonal Affective Depression (SAD) Study	Phase 1
Recruiting	`NCT05503966` - Combining Antidepressants and Attention Bias Modification in Depression	N/A
Recruiting	`NCT03001245` - Interpersonal Counseling (IPC) for Treatment of Depression in Adolescents	N/A
Completed	`NCT02939560` - TMS for Adults With Autism and Depression	N/A
Completed	`NCT02452892` - Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)	N/A
Completed	`NCT02542891` - European Comparative Effectiveness Research on Internet-based Depression Treatment	N/A
Completed	`NCT02224508` - Evaluation of a Health Plan Initiative to Mitigate Chronic Opioid Therapy Risks	N/A
Withdrawn	`NCT02238730` - Ultrabrief Right Unilateral and Brief Pulse Bitemporal Electroconvulsive Therapy	N/A
Completed	`NCT02306551` - Well Being And Resilience: Mechanisms of Transmission of Health and Risk
Completed	`NCT01407575` - Buprenorphine for Treatment Resistant Depression	Phase 3
Completed	`NCT01597661` - Bupropion & Cardio Birth Defect (Slone)	N/A
Completed	`NCT01093053` - Mind-Body Skills Groups for the Treatment of War Zone Stress in Military and Veteran Populations	N/A
Completed	`NCT01829100` - Transdiagnostic Behavioral Activation Therapy for Youth Anxiety and Depression	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.